劳拉替尼治疗ALK阳性晚期NSCLC二期研究最终生物标志物与疗效分析
该全球二期研究对劳拉替尼治疗ALK阳性晚期NSCLC患者进行最终生物标志物与疗效分析,按既往治疗分为三个扩展队列。血浆ctDNA和组织NGS分析显示,EXP2-3A队列中EML4::ALK变异体3与更短OS相关,TP53突变在所有队列中均与更短OS相关;经5年随访,劳拉替尼在初治和经治患者中均显示持续活性并延长OS。
要点
- EXP2-3A队列中ctDNA检出EML4::ALK变异体3者OS短于变异体1或2者。
- TP53突变在所有队列中均与更短OS相关。
- 经5年随访,劳拉替尼在初治和经治患者中均显示持续活性并延长OS。
核心结论
- 经5年随访,该二期研究最终分析进一步支持劳拉替尼在初治和经治ALK阳性晚期NSCLC患者中具有显著活性和延长OS,无论生物标志物亚组如何。
- 初治患者的耐药机制未包括ALK突变的发生。
研究设计与样本
- 全球二期研究,血浆样本在基线和治疗结束时前瞻性收集,患者分为三个扩展队列:EXP1(初治)、EXP2-3A(既往克唑替尼±化疗)、EXP3B-5(既往一种或以上二代ALK TKI±化疗)。
- 采用二代测序分析ctDNA和肿瘤组织样本,基线结果与临床结局进行相关性分析。
- 配对ctDNA样本患者数:EXP1 n=8,EXP2-3A n=17,EXP3B-5 n=64。
主要发现
- EXP2-3A队列中,ctDNA检出EML4::ALK变异体3的患者OS短于变异体1或2患者;EXP1和EXP3B-5队列中无论变异类型均观察到相似OS获益。
- TP53突变在所有队列中均与更短OS相关,肿瘤组织分析结果进一步支持上述观察。
- 配对ctDNA样本中,EXP2-3A和EXP3B-5队列检出获得性ALK突变,EXP1队列未检出。
临床怎么用
- 对既往克唑替尼±化疗后接受劳拉替尼的患者,可考虑通过ctDNA检测EML4::ALK变异体3和TP53突变以辅助预后评估。
- 初治患者接受劳拉替尼治疗后的耐药机制可能不包括ALK突变,与经治患者不同。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: In patients treated with lorlatinib after failure of a second-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI), ALK mutations were identified as a potential marker of response. To identify other correlates, we evaluated ALK fusion subtypes and co-mutations to predict clinical outcomes with lorlatinib and identify potential resistance mechanisms. METHODS: Plasma samples were prospectively collected at baseline and at the end of treatment from patients enrolled in the global phase 2 study, who were divided into three expansion cohorts (EXPs): EXP1 (treatment-naive), EXP2-3A (prior crizotinib ± chemotherapy), and EXP3B-5 (one or more prior second-generation ALK TKI ± chemotherapy). Circulating tumor DNA (ctDNA) and tumor tissue samples were analyzed using next-generation sequencing, and the baseline results were correlated with clinical outcomes. RESULTS: In the EXP2-3A cohort, patients with EML4::ALK fusion variant 3 detected by ctDNA analysis had shorter overall survival (OS) than those with variants 1 or 2; a similar OS benefit was observed regardless of variant type in EXP1 and EXP3B-5 cohorts. The presence of a TP53 mutation was associated with shorter OS in all cohorts. These observations were further supported by tumor tissue analysis results. In patients with matched paired ctDNA samples (EXP1, n = 8; EXP2-3A, n = 17; EXP3B-5, n = 64), acquired ALK mutations were detected in the EXP2-3A and EXP3B-5 cohorts but not in the EXP1 cohort. CONCLUSIONS: After 5 years of follow-up, final analyses from this phase 2 study further supported substantial activity and prolonged OS with lorlatinib in treatment-naive and previously treated patients with ALK-positive advanced NSCLC, regardless of the biomarker subgroups. The resistance mechanisms in treatment-naive patients did not include the emergence of ALK mutations. GOV REGISTRATION: NCT01970865.
引用
- Bauer TM, Martini JF, Besse B, et al. Final Biomarker and Efficacy Analyses of Lorlatinib in Patients With ALK-Positive Advanced NSCLC in a Phase 2 Study. J Thorac Oncol. 2026. PMID: 42749050. doi:10.1016/j.jtho.2026.104202
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。